Olaptesed pegol

Drug Profile

Olaptesed pegol

Alternative Names: Anti-CXCL12/SDF-1 Spiegelmer®; NOX-A12

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator NOXXON Pharma AG
  • Class Antineoplastics; Oligonucleotides; Polyethylene glycols
  • Mechanism of Action Chemokine CXCL12 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Multiple myeloma
  • Preclinical Glioblastoma; Solid tumours
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 15 Dec 2016 NOXXON Pharma entered into a collaboration agreement with Merck for a phase I/II trial
  • 15 Dec 2016 NOXXON plans a phase I/II trial for Solid tumour (Metastatic) in Europe
  • 11 Oct 2016 Pharmacodynamics data from a preclinical trial in Solid tumours (Combination therapy) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top